TWI856945B - 用抗tslp抗體治療氣喘 - Google Patents
用抗tslp抗體治療氣喘 Download PDFInfo
- Publication number
- TWI856945B TWI856945B TW107112622A TW107112622A TWI856945B TW I856945 B TWI856945 B TW I856945B TW 107112622 A TW107112622 A TW 107112622A TW 107112622 A TW107112622 A TW 107112622A TW I856945 B TWI856945 B TW I856945B
- Authority
- TW
- Taiwan
- Prior art keywords
- seq
- amino acid
- antibody
- acid sequence
- light chain
- Prior art date
Links
- 208000006673 asthma Diseases 0.000 title claims abstract description 198
- 238000011282 treatment Methods 0.000 title claims description 57
- 102100031294 Thymic stromal lymphopoietin Human genes 0.000 claims abstract description 86
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 234
- 230000027455 binding Effects 0.000 claims description 119
- 108091033319 polynucleotide Proteins 0.000 claims description 79
- 102000040430 polynucleotide Human genes 0.000 claims description 79
- 239000002157 polynucleotide Substances 0.000 claims description 79
- 208000037874 Asthma exacerbation Diseases 0.000 claims description 73
- 239000000427 antigen Substances 0.000 claims description 73
- 102000036639 antigens Human genes 0.000 claims description 73
- 108091007433 antigens Proteins 0.000 claims description 73
- 239000012634 fragment Substances 0.000 claims description 60
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims description 57
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims description 57
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 claims description 56
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 claims description 56
- 210000003979 eosinophil Anatomy 0.000 claims description 48
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims description 40
- 210000004027 cell Anatomy 0.000 claims description 39
- 208000024891 symptom Diseases 0.000 claims description 36
- 239000003246 corticosteroid Substances 0.000 claims description 33
- 230000000694 effects Effects 0.000 claims description 33
- 241000282414 Homo sapiens Species 0.000 claims description 32
- 101000845170 Homo sapiens Thymic stromal lymphopoietin Proteins 0.000 claims description 32
- 238000013313 FeNO test Methods 0.000 claims description 28
- 239000003814 drug Substances 0.000 claims description 28
- 150000001413 amino acids Chemical class 0.000 claims description 26
- 230000000295 complement effect Effects 0.000 claims description 25
- 238000002560 therapeutic procedure Methods 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 18
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 14
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 14
- 230000002327 eosinophilic effect Effects 0.000 claims description 14
- 229940127212 long-acting beta 2 agonist Drugs 0.000 claims description 13
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 10
- 238000009472 formulation Methods 0.000 claims description 10
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 7
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 7
- 206010036790 Productive cough Diseases 0.000 claims description 7
- 239000012530 fluid Substances 0.000 claims description 7
- 229940124624 oral corticosteroid Drugs 0.000 claims description 7
- 210000003802 sputum Anatomy 0.000 claims description 7
- 208000024794 sputum Diseases 0.000 claims description 7
- 101100495352 Candida albicans CDR4 gene Proteins 0.000 claims description 6
- 102000025171 antigen binding proteins Human genes 0.000 claims description 6
- 108091000831 antigen binding proteins Proteins 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 6
- 238000003745 diagnosis Methods 0.000 claims description 6
- 239000003199 leukotriene receptor blocking agent Substances 0.000 claims description 6
- 229940127211 short-acting beta 2 agonist Drugs 0.000 claims description 6
- 238000007920 subcutaneous administration Methods 0.000 claims description 6
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 5
- 210000004072 lung Anatomy 0.000 claims description 5
- -1 monomeric antibodies Proteins 0.000 claims description 5
- 229950008998 tezepelumab Drugs 0.000 claims description 5
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 claims description 3
- 230000001934 delay Effects 0.000 claims description 3
- 238000001990 intravenous administration Methods 0.000 claims description 3
- 229960000278 theophylline Drugs 0.000 claims description 3
- 241000282412 Homo Species 0.000 claims description 2
- 229940109248 cromoglycate Drugs 0.000 claims description 2
- 239000003149 muscarinic antagonist Substances 0.000 claims description 2
- 108010029307 thymic stromal lymphopoietin Proteins 0.000 abstract description 79
- 238000000034 method Methods 0.000 abstract description 38
- 229940068196 placebo Drugs 0.000 description 74
- 239000000902 placebo Substances 0.000 description 74
- 238000004458 analytical method Methods 0.000 description 46
- 102000004196 processed proteins & peptides Human genes 0.000 description 41
- 108090000765 processed proteins & peptides Proteins 0.000 description 41
- 241000699660 Mus musculus Species 0.000 description 40
- 229940124630 bronchodilator Drugs 0.000 description 31
- 230000008859 change Effects 0.000 description 23
- 235000001014 amino acid Nutrition 0.000 description 20
- 230000002411 adverse Effects 0.000 description 17
- 230000007423 decrease Effects 0.000 description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
- 102000004127 Cytokines Human genes 0.000 description 15
- 108090000695 Cytokines Proteins 0.000 description 15
- 201000010099 disease Diseases 0.000 description 14
- 102000015696 Interleukins Human genes 0.000 description 12
- 108010063738 Interleukins Proteins 0.000 description 12
- 230000005713 exacerbation Effects 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 12
- 239000013566 allergen Substances 0.000 description 11
- 229940125369 inhaled corticosteroids Drugs 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 206010020751 Hypersensitivity Diseases 0.000 description 10
- 206010061218 Inflammation Diseases 0.000 description 10
- 230000004054 inflammatory process Effects 0.000 description 10
- 229920001184 polypeptide Polymers 0.000 description 10
- 208000010668 atopic eczema Diseases 0.000 description 9
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 9
- 229960002714 fluticasone Drugs 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 238000012216 screening Methods 0.000 description 9
- 108060003951 Immunoglobulin Proteins 0.000 description 8
- 230000000172 allergic effect Effects 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 230000006866 deterioration Effects 0.000 description 8
- 229940112141 dry powder inhaler Drugs 0.000 description 8
- 102000018358 immunoglobulin Human genes 0.000 description 8
- 230000037361 pathway Effects 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 238000006467 substitution reaction Methods 0.000 description 8
- 206010014950 Eosinophilia Diseases 0.000 description 7
- 102000013691 Interleukin-17 Human genes 0.000 description 7
- 108050003558 Interleukin-17 Proteins 0.000 description 7
- 108090000978 Interleukin-4 Proteins 0.000 description 7
- 102000004388 Interleukin-4 Human genes 0.000 description 7
- 239000000090 biomarker Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 229940047122 interleukins Drugs 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 230000002459 sustained effect Effects 0.000 description 7
- 230000009885 systemic effect Effects 0.000 description 7
- 102100037765 Periostin Human genes 0.000 description 6
- 101710199268 Periostin Proteins 0.000 description 6
- 208000037883 airway inflammation Diseases 0.000 description 6
- 208000026935 allergic disease Diseases 0.000 description 6
- 230000007815 allergy Effects 0.000 description 6
- 229960001334 corticosteroids Drugs 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 238000012423 maintenance Methods 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- 108090000176 Interleukin-13 Proteins 0.000 description 5
- 102000003816 Interleukin-13 Human genes 0.000 description 5
- 108010002616 Interleukin-5 Proteins 0.000 description 5
- 102000000743 Interleukin-5 Human genes 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 230000007613 environmental effect Effects 0.000 description 5
- 210000003630 histaminocyte Anatomy 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 229940127558 rescue medication Drugs 0.000 description 5
- 230000000391 smoking effect Effects 0.000 description 5
- 238000013125 spirometry Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 102100030703 Interleukin-22 Human genes 0.000 description 4
- 108020004511 Recombinant DNA Proteins 0.000 description 4
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 201000009961 allergic asthma Diseases 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 235000018417 cysteine Nutrition 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 102000045535 human TSLP Human genes 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 238000013105 post hoc analysis Methods 0.000 description 4
- 239000000600 sorbitol Substances 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 3
- 102100038497 Cytokine receptor-like factor 2 Human genes 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010022095 Injection Site reaction Diseases 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 102000000588 Interleukin-2 Human genes 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 230000004988 N-glycosylation Effects 0.000 description 3
- 206010035664 Pneumonia Diseases 0.000 description 3
- 206010035742 Pneumonitis Diseases 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 210000004241 Th2 cell Anatomy 0.000 description 3
- 102100040247 Tumor necrosis factor Human genes 0.000 description 3
- 206010047924 Wheezing Diseases 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000009175 antibody therapy Methods 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 150000001720 carbohydrates Chemical group 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 3
- 230000006735 deficit Effects 0.000 description 3
- 210000004443 dendritic cell Anatomy 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 208000024711 extrinsic asthma Diseases 0.000 description 3
- 239000003862 glucocorticoid Substances 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 201000010659 intrinsic asthma Diseases 0.000 description 3
- 230000004199 lung function Effects 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 229940068977 polysorbate 20 Drugs 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 101000956427 Homo sapiens Cytokine receptor-like factor 2 Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- 102000003814 Interleukin-10 Human genes 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 description 2
- 208000037656 Respiratory Sounds Diseases 0.000 description 2
- 102000007562 Serum Albumin Human genes 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 210000000447 Th1 cell Anatomy 0.000 description 2
- 210000000068 Th17 cell Anatomy 0.000 description 2
- 101150072278 Tslp gene Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 230000010085 airway hyperresponsiveness Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000008236 biological pathway Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000004067 bulking agent Substances 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 230000020411 cell activation Effects 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000009266 disease activity Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 230000002996 emotional effect Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 108010074108 interleukin-21 Proteins 0.000 description 2
- 108010074109 interleukin-22 Proteins 0.000 description 2
- 229940028885 interleukin-4 Drugs 0.000 description 2
- 229940100602 interleukin-5 Drugs 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000003563 lymphoid tissue Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 230000003448 neutrophilic effect Effects 0.000 description 2
- 150000007523 nucleic acids Chemical group 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 208000013220 shortness of breath Diseases 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 208000036065 Airway Remodeling Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 206010008469 Chest discomfort Diseases 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 101710194733 Cytokine receptor-like factor 2 Proteins 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101000998146 Homo sapiens Interleukin-17A Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 102100033461 Interleukin-17A Human genes 0.000 description 1
- 108090000171 Interleukin-18 Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108010067003 Interleukin-33 Proteins 0.000 description 1
- 102000017761 Interleukin-33 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 241001024304 Mino Species 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 238000001358 Pearson's chi-squared test Methods 0.000 description 1
- 241000288049 Perdix perdix Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 description 1
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229930194936 Tylosin Natural products 0.000 description 1
- 239000004182 Tylosin Substances 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 238000011374 additional therapy Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 210000001552 airway epithelial cell Anatomy 0.000 description 1
- 210000005057 airway smooth muscle cell Anatomy 0.000 description 1
- 229910001508 alkali metal halide Inorganic materials 0.000 description 1
- 150000008045 alkali metal halides Chemical class 0.000 description 1
- 230000009285 allergic inflammation Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000001022 anti-muscarinic effect Effects 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229940127225 asthma medication Drugs 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- XKXHCNPAFAXVRZ-UHFFFAOYSA-N benzylazanium;chloride Chemical compound [Cl-].[NH3+]CC1=CC=CC=C1 XKXHCNPAFAXVRZ-UHFFFAOYSA-N 0.000 description 1
- 229940124748 beta 2 agonist Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 229940107161 cholesterol Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000004547 gene signature Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229960002163 hydrogen peroxide Drugs 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 229940127130 immunocytokine Drugs 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 210000004964 innate lymphoid cell Anatomy 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229940065725 leukotriene receptor antagonists for obstructive airway diseases Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000000581 natural killer T-cell Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 229940067107 phenylethyl alcohol Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 229960002429 proline Drugs 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 235000019375 tylosin Nutrition 0.000 description 1
- WBPYTXDJUQJLPQ-VMXQISHHSA-N tylosin Chemical compound O([C@@H]1[C@@H](C)O[C@H]([C@@H]([C@H]1N(C)C)O)O[C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CC=O)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@H]1C[C@@](C)(O)[C@@H](O)[C@H](C)O1 WBPYTXDJUQJLPQ-VMXQISHHSA-N 0.000 description 1
- 229960004059 tylosin Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762484864P | 2017-04-12 | 2017-04-12 | |
| US62/484,864 | 2017-04-12 | ||
| US201762553575P | 2017-09-01 | 2017-09-01 | |
| US201762553477P | 2017-09-01 | 2017-09-01 | |
| US62/553,477 | 2017-09-01 | ||
| US62/553,575 | 2017-09-01 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201838652A TW201838652A (zh) | 2018-11-01 |
| TWI856945B true TWI856945B (zh) | 2024-10-01 |
Family
ID=62092313
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW107112622A TWI856945B (zh) | 2017-04-12 | 2018-04-12 | 用抗tslp抗體治療氣喘 |
| TW113133318A TW202523688A (zh) | 2017-04-12 | 2018-04-12 | 用抗tslp抗體治療氣喘 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW113133318A TW202523688A (zh) | 2017-04-12 | 2018-04-12 | 用抗tslp抗體治療氣喘 |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US10828365B2 (enExample) |
| EP (1) | EP3609917A1 (enExample) |
| JP (4) | JP7330896B2 (enExample) |
| KR (2) | KR102666879B1 (enExample) |
| CN (1) | CN110573525A (enExample) |
| AU (2) | AU2018253118B2 (enExample) |
| BR (1) | BR112019021482A2 (enExample) |
| CA (1) | CA3059364A1 (enExample) |
| CL (1) | CL2019002897A1 (enExample) |
| CO (1) | CO2019011462A2 (enExample) |
| IL (1) | IL269791B (enExample) |
| JO (1) | JOP20190243A1 (enExample) |
| MX (1) | MX2019012158A (enExample) |
| MY (1) | MY207509A (enExample) |
| PE (1) | PE20200484A1 (enExample) |
| PH (1) | PH12019502331A1 (enExample) |
| SG (1) | SG11201909322VA (enExample) |
| TN (1) | TN2019000289A1 (enExample) |
| TW (2) | TWI856945B (enExample) |
| UY (1) | UY37676A (enExample) |
| WO (1) | WO2018191479A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3347377T (pt) * | 2015-09-09 | 2021-04-30 | Novartis Ag | Anticorpos que se ligam à linfopoietina do estroma tímico (tslp) e métodos de utilização dos anticorpos |
| JOP20190243A1 (ar) * | 2017-04-12 | 2019-10-13 | Medimmune Llc | علاج الربو بجسم مضاد لـ tslp |
| CN116751295A (zh) | 2019-06-04 | 2023-09-15 | 江苏恒瑞医药股份有限公司 | 能结合胸腺基质淋巴细胞生成素的抗体及其应用 |
| EP3996747A4 (en) * | 2019-07-11 | 2023-08-16 | Tavotek Biotherapeutics (Hong Kong) Limited | AGENTS THAT INTERFERE WITH THYMIC STROMAL LYMPHOPOIETIN RECEPTOR (TSLP) SIGNALING |
| JP7331298B2 (ja) * | 2019-09-04 | 2023-08-23 | ビオシオン インコーポレイテッド | 抗体結合ｔｓｌｐ及びその使用 |
| MX2022005083A (es) * | 2019-10-28 | 2022-07-19 | Medimmune Ltd | Formulaciones en polvo seco de anticuerpos de unión a linfopoyetina estromal tímica (tslp) y métodos para usarlos. |
| CN114887053A (zh) * | 2019-11-29 | 2022-08-12 | 康诺亚生物医药科技（成都）有限公司 | 一种tslp相关病症治疗剂的开发和应用 |
| CA3155759A1 (en) * | 2019-12-13 | 2021-06-17 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Anti-tslp antibody and uses thereof |
| TW202140550A (zh) | 2020-01-29 | 2021-11-01 | 瑞士商諾華公司 | 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法 |
| WO2021163588A1 (en) * | 2020-02-13 | 2021-08-19 | Amgen Inc. | Treatment of atopic dermatitis with anti-tslp antibody |
| BR112022016010A2 (pt) * | 2020-02-13 | 2022-12-20 | Amgen Inc | Formulações de anticorpos anti-tslp humanos e métodos de tratamento de doenças inflamatórias |
| CA3167975A1 (en) * | 2020-02-18 | 2021-08-26 | Amgen, Inc. | Formulations of human anti-tslp antibodies and methods of using the same |
| CN113388035A (zh) * | 2020-03-13 | 2021-09-14 | 迈威(上海)生物科技股份有限公司 | 特异性针对人tslp的抗体及其应用 |
| WO2022117079A1 (zh) * | 2020-12-03 | 2022-06-09 | 江苏恒瑞医药股份有限公司 | 结合胸腺基质淋巴细胞生成素的抗体及其应用 |
| CN113501878B (zh) * | 2021-02-03 | 2022-12-02 | 北京智仁美博生物科技有限公司 | 针对人tslp的多种抗体及其用途 |
| CN114853888B (zh) * | 2021-02-05 | 2023-11-03 | 上海洛启生物医药技术有限公司 | 抗tslp纳米抗体及其应用 |
| CN116897053B (zh) * | 2021-03-03 | 2025-01-07 | 正大天晴药业集团股份有限公司 | 含抗tslp抗体的药物组合物 |
| CR20230533A (es) * | 2021-04-19 | 2024-04-05 | Medimmune Ltd | Un fab anti-tslp con estabilidad mejorada |
| EP4326766A1 (en) | 2021-04-23 | 2024-02-28 | Amgen Inc. | Anti-tslp antibody compositions and uses thereof |
| US20240182558A1 (en) | 2021-04-23 | 2024-06-06 | Amgen Inc. | Modified anti-tslp antibodies |
| CN113683694B (zh) * | 2021-09-03 | 2022-05-13 | 江苏荃信生物医药股份有限公司 | 一种抗人tslp单克隆抗体及其应用 |
| CN116217724B (zh) * | 2021-12-02 | 2023-10-27 | 北京东方百泰生物科技股份有限公司 | 一种抗tslp的单克隆抗体、其抗原结合片段及其应用 |
| CN117327176A (zh) * | 2022-06-24 | 2024-01-02 | 南京融捷康生物科技有限公司 | 一种抗tslp的单域抗体及其用途 |
| US12110324B2 (en) | 2022-07-22 | 2024-10-08 | Flagship Pioneering Innovations Vi, Llc | Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP) |
| AR130862A1 (es) | 2022-10-26 | 2025-01-29 | Amgen Inc | Composiciones de anticuerpos anti-tslp y usos de las mismas |
| TW202523697A (zh) * | 2023-08-25 | 2025-06-16 | 美商普羅特歐拉吉克適美國公司 | 抗ｔｓｌｐ抗體構築體及其用途 |
| WO2025049345A1 (en) | 2023-08-25 | 2025-03-06 | Proteologix Us Inc. | Anti-il-13 multispecific antibody constructs and uses thereof |
| CN117551195B (zh) * | 2024-01-12 | 2024-04-09 | 杭州畅溪制药有限公司 | 靶向tslp的vhh纳米抗体及其应用 |
| WO2025179220A1 (en) * | 2024-02-22 | 2025-08-28 | Flagship Pioneering Innovations Vi, Llc | Dosing of antigen binding molecules targeting thymic stromal lymphopoietin (tslp) |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| WO1991010741A1 (en) | 1990-01-12 | 1991-07-25 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| AU675661B2 (en) | 1992-07-24 | 1997-02-13 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| DE69637481T2 (de) | 1995-04-27 | 2009-04-09 | Amgen Fremont Inc. | Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8 |
| US7982016B2 (en) * | 2007-09-10 | 2011-07-19 | Amgen Inc. | Antigen binding proteins capable of binding thymic stromal lymphopoietin |
| US8359965B2 (en) | 2007-09-17 | 2013-01-29 | Oxford J Craig | Apparatus and method for broad spectrum radiation attenuation |
| TW201018482A (en) | 2008-08-08 | 2010-05-16 | Glaxo Wellcome Mfg Pte Ltd | Novel treatment |
| JP6077856B2 (ja) | 2009-11-04 | 2017-02-08 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 操作型抗ｔｓｌｐ抗体本出願は、米国特許仮出願第６１／２９７，００８号（２０１０年１月２１日出願）、および米国特許仮出願第６１／２５８，０５１号（２００９年１１月４日出願）の利益を主張し、該仮出願は各々、引用によりその全体が本明細書に組み込まれる。 |
| AR082163A1 (es) | 2010-07-15 | 2012-11-14 | Hoffmann La Roche | Anticuerpos especificamente ligantes del tslpr humano y metodos de utilizacion de los mismos |
| US9100245B1 (en) | 2012-02-08 | 2015-08-04 | Amazon Technologies, Inc. | Identifying protected media files |
| US9306926B2 (en) | 2013-03-15 | 2016-04-05 | Brian A. Truong | User authentication using unique hidden identifiers |
| SG11201603127WA (en) * | 2013-10-23 | 2016-05-30 | Genentech Inc | Methods of diagnosing and treating eosinophilic disorders |
| SG11201700901SA (en) * | 2014-08-08 | 2017-03-30 | Alector Llc | Anti-trem2 antibodies and methods of use thereof |
| CN107428828A (zh) * | 2015-03-11 | 2017-12-01 | 葛兰素史密斯克莱知识产权发展有限公司 | Tslp结合蛋白 |
| EA038332B1 (ru) | 2015-09-09 | 2021-08-10 | Новартис Аг | Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул |
| JOP20190243A1 (ar) * | 2017-04-12 | 2019-10-13 | Medimmune Llc | علاج الربو بجسم مضاد لـ tslp |
-
2017
- 2017-06-16 JO JOP/2019/0243A patent/JOP20190243A1/ar unknown
-
2018
- 2018-04-12 MX MX2019012158A patent/MX2019012158A/es unknown
- 2018-04-12 AU AU2018253118A patent/AU2018253118B2/en active Active
- 2018-04-12 CN CN201880026131.3A patent/CN110573525A/zh active Pending
- 2018-04-12 KR KR1020197033043A patent/KR102666879B1/ko active Active
- 2018-04-12 TN TNP/2019/000289A patent/TN2019000289A1/en unknown
- 2018-04-12 BR BR112019021482-8A patent/BR112019021482A2/pt unknown
- 2018-04-12 TW TW107112622A patent/TWI856945B/zh active
- 2018-04-12 IL IL269791A patent/IL269791B/en unknown
- 2018-04-12 WO PCT/US2018/027271 patent/WO2018191479A1/en not_active Ceased
- 2018-04-12 PE PE2019002026A patent/PE20200484A1/es unknown
- 2018-04-12 CA CA3059364A patent/CA3059364A1/en active Pending
- 2018-04-12 UY UY0001037676A patent/UY37676A/es not_active Application Discontinuation
- 2018-04-12 TW TW113133318A patent/TW202523688A/zh unknown
- 2018-04-12 US US15/951,602 patent/US10828365B2/en active Active
- 2018-04-12 SG SG11201909322V patent/SG11201909322VA/en unknown
- 2018-04-12 EP EP18721605.6A patent/EP3609917A1/en active Pending
- 2018-04-12 MY MYPI2019005927A patent/MY207509A/en unknown
- 2018-04-12 JP JP2019555854A patent/JP7330896B2/ja active Active
- 2018-04-12 KR KR1020247015858A patent/KR20240070727A/ko active Pending
-
2019
- 2019-10-11 PH PH12019502331A patent/PH12019502331A1/en unknown
- 2019-10-11 CL CL2019002897A patent/CL2019002897A1/es unknown
- 2019-10-16 CO CO2019011462A patent/CO2019011462A2/es unknown
-
2020
- 2020-11-09 US US17/093,387 patent/US20210052726A1/en not_active Abandoned
-
2023
- 2023-05-15 JP JP2023080295A patent/JP2023099233A/ja not_active Withdrawn
-
2024
- 2024-08-02 JP JP2024127900A patent/JP2024150751A/ja active Pending
- 2024-10-08 US US18/909,660 patent/US20250032608A1/en active Pending
-
2025
- 2025-06-24 AU AU2025204735A patent/AU2025204735A1/en active Pending
- 2025-09-04 JP JP2025147176A patent/JP2025170430A/ja active Pending
Non-Patent Citations (1)
| Title |
|---|
| 網路文獻 NCT02512900. A Phase 1, Open-label Study to Evaluate the Pharmacokinetics of MEDI9929 (AMG 157) in Adolescents With Mild to Moderate Asthma. Results First Posted：2017-02-23 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI856945B (zh) | 用抗tslp抗體治療氣喘 | |
| EP2152290B1 (en) | Methods for administering anti-il-5 antibodies | |
| EP2627673B1 (en) | Therapies for improving pulmonary function | |
| US20180319889A1 (en) | Method and medicament for treating airway and/or lung diseases | |
| US20230081261A1 (en) | Formulations of human anti-tslp antibodies and methods of using the same | |
| TW202304980A (zh) | 經修飾的抗ｔｓｌｐ抗體 | |
| US20230073888A1 (en) | Treatment of atopic dermatitis with anti-tslp antibody | |
| TW202509066A (zh) | 用抗ｔｓｌｐ抗體治療皮質類固醇依賴性氣喘 | |
| KR20250140101A (ko) | 항-tslp 항체를 이용한 만성 비부비동염의 치료 | |
| WO2025221247A1 (en) | Treatment of eosinophilic esophagitis with anti-tslp antibody | |
| WO2025147632A1 (en) | Treatment of chronic obstructive pulmonary disease with anti-tslp antibody | |
| HK1188603A (en) | Therapies for improving pulmonary function | |
| HK1188603B (en) | Therapies for improving pulmonary function |